Fig. 2From: Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case reportShrinkage of the patient’s intra-hepatic lesions after two months of olaparib treatment. CT scan of the abdomen before (a) and after (b) two months of olaparib treatmentBack to article page